Selenium has a similar effect, no more than 400mcg/day.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT - News), .....announced that at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, commented on the involvement of the immune system in response to PV-10 therapy and its role in the “bystander effect” in treating metastatic melanoma. Dr. Agarwala’s presentation, entitled “Chemoablation in Melanoma: An Update,” was given in the session entitled “Unique Approaches to Melanoma Therapy.”
Dr. Agarwala, Chief, Medical Oncology and Hematology at St. Luke’s Hospital and Health Network in Bethlehem, PA, and Principal Investigator for Provectus’s Phase 2 PV-10 trial site at St. Luke’s, noted, “PV-10 is of particular interest to me as an oncologist because it appears to recruit immune cells to the ablation site, leading to the potential of a systemic benefit. Efficacy data from Phase 1 and from the current Phase 2 study demonstrate a close correlation between objective response in treated lesions and response in uninjected lesions. Survival data from both studies further support a conclusion that patients that respond well to PV-10 respond well overall.”
.